BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California.
In July 2021, BioLegend was acquired by PerkinElmer for $5.25 billion and now operates as Revvity.
Reagents are created for use in flow cytometry, proteogenomics, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.
In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen.
[4] In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis.